The quest to overcome resistance to EGFR-targeted therapies in cancer

被引：0
|
作者：
Curtis R Chong
Pasi A Jänne
机构：
[1] Lowe Center for Thoracic Oncology,Department of Medicine
[2] Dana-Farber Cancer Institute,undefined
[3] Brigham and Women's Hospital,undefined
[4] Belfer Institute for Applied Cancer Science,undefined
[5] Dana-Farber Cancer Institute,undefined
来源：
Nature Medicine | 2013年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite the initial promise of cancer therapies targeted against the epidermal growth factor receptor (EGFR), tumors treated with these agents eventually develop resistance. In this Review, the authors outline the complex mechanisms by which tumors become resistant to EGFR-targeted drugs and antibodies and offer insights into new strategies that might be employed to circumvent therapeutic resistance.
引用
收藏
页码：1389 / 1400
页数：11
相关论文
共 50 条
  • [31] EGFR Expression and KRAS Mutation in Cholangiocarcinoma: Implication in EGFR-Targeted Therapies
    Fan, L. F.
    Datta, V.
    Riley-Portuges, A.
    Lopategui, J.
    Lin, F.
    Xu, H.
    Wang, H. L.
    MODERN PATHOLOGY, 2010, 23 : 354A - 354A
  • [32] Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    David Z Chang
    Vikas Kumar
    Ying Ma
    Kuiyuan Li
    Scott Kopetz
    Journal of Hematology & Oncology, 2
  • [33] Resistance to EGFR-Targeted Therapy: A Family Affair
    Vlacich, Gregory
    Coffey, Robert J.
    CANCER CELL, 2011, 20 (04) : 423 - 425
  • [34] Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Nicola Normanno
    Sabine Tejpar
    Floriana Morgillo
    Antonella De Luca
    Eric Van Cutsem
    Fortunato Ciardiello
    Nature Reviews Clinical Oncology, 2009, 6 : 519 - 527
  • [35] Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
    Beata Zahorowska
    Philip J. Crowe
    Jia-Lin Yang
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1137 - 1148
  • [36] KRAS mutational testing in the selection of patients for EGFR-targeted therapies
    Garcia, Joaquin
    Riely, Gregory J.
    Nafa, Khedoudja
    Ladanyi, Marc
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2008, 25 (04) : 288 - 294
  • [37] Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Normanno, Nicola
    Tejpar, Sabine
    Morgillo, Floriana
    De Luca, Antonella
    Van Cutsem, Eric
    Ciardiello, Fortunato
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (09) : 519 - 527
  • [38] Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
    Zahorowska, Beata
    Crowe, Philip J.
    Yang, Jia-Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (09) : 1137 - 1148
  • [39] Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
    Giovannini, Monica
    Gregorc, Vanesa
    Belli, Carmen
    Roca, Elisa
    Lazzari, Chiara
    Vigano, Maria Grazia
    Serafico, Anna
    Villa, Eugenio
    JOURNAL OF ONCOLOGY, 2009, 2009
  • [40] Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
    Favorito, Valentina
    Ricciotti, Ilaria
    De Giglio, Andrea
    Fabbri, Laura
    Seminerio, Renata
    Di Federico, Alessandro
    Gariazzo, Eleonora
    Costabile, Silvia
    Metro, Giulio
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (02) : 139 - 154
12345